SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Mechanism of Action
Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways.
Dosage Overview
Dose Range
1 mg – 5 mg
Route
subcutaneous
Frequency
1x daily
Cycle Length
4–8 weeks
Reconstitution
Typical Dosage (Research)
Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established.
Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties.
Considerations for Men & Women
Women: Small humanin-like peptide with cytoprotective effects. Very limited human data. No established sex-specific differences. Standard pregnancy precautions due to insufficient safety data.
Men: Same research protocols. Limited clinical data for both sexes.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 2,500 mcg/ml
Volume to inject: 0.40 ml
Syringe units (U-100): 40.0 units
Pre-filled with SHLP2 defaults. Adjust values as needed.
Side Effects & Risks
Limited data. Animal studies suggest good tolerability. May affect glucose metabolism.
Highly experimental. Most data from animal models. Human safety and efficacy not established.
Who Uses SHLP2
Researchers studying mitochondrial-derived peptides, those interested in cutting-edge longevity research.
Similar Peptides
View All Alternatives →Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.